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Abstract: IgG4-related lymphadenopathy (IgG4-LAD) is newly described entity, which may occur before, during or 
after diagnosis of extranodal IgG4-related disease. It is important to recognize IgG4-LAD, especially in cases with 
lymphadenopathy as the initial presentation, so that the patients can receive prompt treatment. However, it can 
be challenging to formulate a final diagnosis since IgG4-LAD displays a broad morphologic spectrum. Moreover, 
morphologic changes alone are not sufficient for diagnosis of IgG4-LAD, and an accurate diagnosis has to take into 
account of the overall clinical presentations and laboratory studies. Currently, it is not very clear when pathologists 
should consider workup for potential IgG4-LAD based on the histologic features. Particularly, for some pathologists, 
it is not certain how to render the diagnosis in reactive lymph nodes with markedly increased IgG4 + cells. In this 
review, we will attempt to summarize the major clinicopathologic features of IgG4-LAD and its variants, differential 
diagnoses, and algorithms to establish an accurate diagnosis.
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Introduction
IgG4-related disease (IgG4-RD) is a recently 
recognized fibroinflammatory condition, which 
was initially described in the pancreas as “scle-
rosing pancreatitis”, now referred to as “type I 
IgG4-related autoimmune pancreatitis” [1]. 
Nowadays, IgG4-RD has been diagnosed in 
nearly all organ systems, including the pancre-
as, lacrimal glands, salivary glands, kidneys, 
lungs, prostate, lymph nodes, aorta, and skin 
[2-4]. IgG4-RD mostly occurs in middle-aged to 
elderly men. The patients typically present with 
an indolent clinical course, and the signs and 
symptoms may become evident over months or 
years. Constitutional symptoms are generally 
absent, including weight loss, fevers, fatigue, 
malaise, and night sweats. Up to 30-40% of 
patients may have a longstanding history of 
allergies at diagnosis. Diagnosis of IgG4-RD 
is based upon the clinical presentations, sero-
logic studies, and histomorphologic features 
[4-10]. Serum IgG4 levels (normal 135 mg/dL) 
are elevated in the majority of patients, espe-
cially those with multi-organ involvement [7, 
11]. However, elevation in serum IgG4 levels 
can be detected in conditions other than IgG4-
RD, including systemic vasculitis, connective 
tissue disorders, infections, and malignancies 
[12]. Glucocorticoids are typically the first line 
of therapy, which are effective in most patients 
initially. Rituximab and methotrexate are useful 
for recurrent or refractory diseases [3, 13].
In the extranodal sites, IgG4-RD typically pres-
ents as mass or pseudotumour-like lesions in a 
single or multiple organs with very similar histo-
pathological findings. Three major morphologic 
characteristics have been described [6] (Figure 
1A-E): (1) Dense lymphoplasmacytic infiltrate 
with increased IgG4+ cells; (2) Fibrosis, typically 
showing prominent fibroblastic proliferation 
with a characteristic storiform growth pattern; 
(3) Obliterative phlebitis, although this feature 
is difficult to find in many cases of IgG4-RD. 
Other minor histopathological features associ-
ated with IgG4-RD include non-obliterative ph- 
lebitis and increased eosinophils in the tissue. 
IgG4-related lymphadenopathy (IgG4-LAD) is 
noted in approximately 80% of patients with 
extranodal IgG4-RD [14]. It can appear before, 
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concurrent with, or after the diagnosis of the 
extranodal disease. In the cases with lymph-
adenopathy as the initial presentation, it is criti-
cal to recognize IgG4-LAD so that the patients 
can receive timely treatment to avoid irrevers-
ible vital organ damages, destructive surgeries 
or life-threatening events in other systems. 
However, diagnosis of IgG4-LAD can be chal-
lenging for several reasons: (1) IgG4-LAD has 
not been widely recognized by pathologists, 
and therefore it can be under-diagnosed due to 
lack of awareness of such entity; (2) The patho-
logic changes in lymph nodes display a broad 
morphologic spectrum and greatly overlap with 
Figure 1. A case of IgG4-RD involving submandibular gland. (A, B) Extensive fibrosis and prominent lymphoid infil-
tration with scattered reactive lymphoid follicles (H&E, 40 × and 100 ×, respectively). (C) Storiform arrangement of 
fibroblastic proliferation and prominent lymphoplasmacytic infiltration (H&E, 200 ×). (D) An obliterated vein (H&E, 
100 ×) with elastin stain (E) (100 ×). (F) Abundant IgG4+ cells in the tissue (200 ×).
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those in non-IgG4-related lymphadenopathy, 
which could result in potential over-diagnosis; 
and (3) IgG4-LAD is not purely a morphologic 
diagnosis, and a definitive diagnosis has to rely 
on the overall clinical presentations, histology 
changes, and laboratory studies. 
General features of IgG4-LAD
Patients with IgG4-LAD have similar clinical 
presentations to those with extranodal IgG4-
RD, and they typically present with enlarged 
lymph nodes without constitutional symptoms. 
The lymph nodes are non-tender and measure 
1 to 3 cm in greatest dimension. Lymphade- 
nopathy can be localized or generalized and 
often associated with extranodal lesions. For 
example, approximately 80% of patients with 
IgG4-related pancreatitis have concurrent in- 
volvement of lymph nodes, particularly the 
mediastinal and intraabdominal lymph nodes 
[14]. However, lymphadenopathy can some-
times be the first manifestation of IgG4-RD, 
which places great challenge to pathologists in 
diagnosis. 
IgG4-LAD displays a broad morphologic spec-
trum, and five histologic subtypes have been 
described, including (1) Multicentric Castleman 
disease-like; (2) Reactive follicular hyperplasia-
like; (3) Interfollicular expansion and immuno-
blastosis; (4) Progressive transformation of ger-
minal center (PTGC) type; and (5) Inflammatory 
pseudotumor-like. Morphologic overlaps exist 
among different subtypes, and therefore some-
times it may not be feasible to accurately sub-
classify IgG4-LAD. Compared to the extranodal 
IgG4-RD, the histologic changes in IgG4-LAD 
are different: obliterative phlebitis is usually 
absent in all subtype of IgG4-LAD and the char-
acteristic storiform fibrosis is usually absent 
except for the inflammatory pseudotumor-like 
subtype. 
Studies have suggested that in lymph nodes an 
IgG4+ cell count of ≥ 100 cells per high power 
field (HFP) and an IgG4+/IgG+ cell ratio of ≥ 
40% are the necessary cutoff values in diagno-
sis of IgG4-LAD [15]. IgG4 and IgG immunos-
tainings are strongly recommended in any case 
suspicious for IgG4-LAD, and they have been 
proved to be very simple and powerful. Dis- 
tribution of IgG4+ cells in lymph nodes can be 
patchy, and counting areas with intense IgG4+ 
cells might be more appropriate. It is recom-
mended that at least three 40 × fields (0.196 
mm2) with the highest number of IgG4+ cells 
should be counted to calculate the average 
number of IgG4+ cells within these fields [15]. 
The same three fields should be counted for 
IgG+ cells to calculate the IgG4+/IgG+ cell ratio. 
We must emphasize that the morphology alone 
is essential but not sufficient for a diagnosis 
of IgG4-LAD, even in cases with significantly 
increased IgG4+ cells and elevated IgG4+/IgG+ 
cell ratio. Several non-IgG4-LAD disease enti-
ties may also show increased IgG4+ cells and 
elevated IgG4+/IgG + cell ratios in lymph nodes, 
including conditions associated with elevated 
serum interleukin-6 (IL-6) concentrations (such 
as multicentric Castleman disease and rh- 
eumatoid arthritis), infections, Rosai-Dorfman 
Figure 2. A case of type I IgG4-LAD with multicentric Castleman disease-like features. A. The lymph node shows in-
terfollicular expansion and frequent regressive lymphoid follicles, one of which has a penetrating vessel (right side) 
(H&E, 200 ×). B. Abundant IgG4+ cells are noted in the interfollicular areas (200 ×).
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disease, and lymphomas [15-17]. Correlation 
with clinical findings and laboratory studies is 
crucial for an accurate diagnosis. The detailed 
differential diagnoses will be discussed in each 
section below. 
Morphologic subtypes of IgG4-LAD
Type I IgG4-LAD: multicentric Castleman 
disease-like
The patient with type I IgG4-LAD often presents 
with systemic lymphadenopathy. Histologically, 
the nodal architecture is preserved with follicu-
lar hyperplasia, variable degrees of interfollicu-
lar expansion, and patent sinusoids (Figure 
2A). Frequent reactive lymphoid follicles have 
regressive germinal centers, and occasional 
follicles may contain penetrating blood vesse- 
ls, reminiscent of those seen in conventional 
Castleman disease. Normal to hyperplastic ger-
minal centers are also present. The mantle 
zones are often expanded. The interfollicular 
areas are expanded with abundant plasma 
cells, scattered eosinophils, and prominent 
proliferation of high endothelial venules. The 
IgG4+ cells are mostly in the interfollicular 
areas with an IgG4+ cell count ≥ 100 per HPF 
and an IgG4/IgG ratio ≥ 40% (Figure 2B). 
Type I IgG4-LAD morphologically overlaps sig-
nificantly with multicentric Castleman disease 
(MCD) and these two entities have to be sepa-
rated (Table 1). Clinically, type I IgG4-LAD typi-
cally occurs in patients with no history of HIV 
infection, and the patients mostly lack constitu-
tional symptoms despite systemic lymphade-
nopathy. Patients usually have no anemia, hy- 
poalbuminemia, or hypocholesterolemia [18]. 
Serology studies often detect elevated IgG 
(mostly due to elected IgG4) and IgE, whereas 
IgA, IgM, IL6 and C-reactive protein (CRP) levels 
are mostly normal. On the other hand, MCD is 
often associated with constitutional symptoms 
in HIV+ patients, and serum immunoglobulins 
(IgA, IgG and IgM), IL6 and CRP are elevated. 
The morphologic features are similar in type I 
IgG4-LAD and MCD; however, in MCD the reac-
tive germinal centers are mostly small and 
regressed, in contrast to a morphologic spec-
trum of germinal centers in type I IgG4-LAD. 
Interfollicular eosinophils are rare or absent in 
MCD. Although IgG4+ cells are typically not 
increased in MCD, some cases of MCD may 
have a marked increase in IgG4+ cell (≥ 100 
per HPF), an IgG4/IgG ratio ≥ 40%, and elevat-
ed serum IgG4 levels, which would fulfill the 
morphologic diagnostic criteria for IgG4-RD. 
Therefore, these two entities may not be fully 
differentiated just based on the histological 
findings, IgG4+ cells in the tissue, and serum 
IgG4 levels; clinical presentations and addition-
al laboratory analyses are essential for a defini-
tive diagnosis.
Non-specific reactive lymphadenopathy with 
Castleman-like features can be encountered 
occasionally with no identifiable underlying eti-
ology. The lymphadenopathy is usually local-
ized and lymph node may reach a substantially 
large size. The reactive lymphoid follicles usu-
ally contain regressed to hyperplastic germinal 
centers and expanded mantle zones. The inter-
Table 1. Comparison between type I IgG4-LAD and multicentric Castleman disease (Modified from [4])
Type I IgG4-LAD Multicentric Castleman Disease
Presentations Typically asymptomatic with or without extranodal IgG4-RD. 
No constitutional symptoms
Abrupt or gradual onset of symptoms, with multiple lymph-
adenopathy and constitutional symptoms
Age Middle-aged to elderly, median age 69 years Middle-aged to elderly, median age 64 years
Gender Marked male predilection, M:F=8:1 M:F=2:1
HIV Status Negative Often positive
Serum immunoglobulin Elevated IgG, IgG4 and IgE levels; normal IgM and IgA levels Globally elevated, including IgG, IgM and IgA levels
Serum IL6 Normal or mildly increased Increased
C-reactive protein Normal or mildly increased Increased
Anemia No or mild Common, often moderate to severe
Histology Preserved architecture. Regressive, normal to hyperplastic 
follicles. Interfollicular zones often rich in plasma cells and 
eosinophils
Preserved architecture. Usually small and regressed lym-
phoid follicles. Interfollicular areas with florid plasmacyto-
sis but no eosinophilia
Immunostains Increased IgG4+ cells and IgG4/IgG ratio. No light chain 
restriction
Usually no increase in IgG4+ cells. May have lambda light 
chain restriction. HHV8 often positive
Prognosis Benign clinical course; good response to steroid therapy Unpredictable clinical course, but often with high mortality
IgG4-related lymphadenopathy
10157 Int J Clin Exp Pathol 2017;10(10):10153-10166
follicular regions often demonstrate a mixed 
lymphoid proliferation with no significant in- 
crease in plasma cells or eosinophils. Most 
cases have no elevated IgG4+ cells or IgG4/IgG 
ratio, although some may have a significant 
increase in IgG4+ cells with no association with 
IgG4-RD. The lymphocyte-rich variant of classic 
Hodgkin lymphoma (CHL) may show a nodular 
growth pattern with an expanded mantle zone 
and a regressed and eccentrically placed ger-
minal center, sometimes reminiscent of Cas- 
tleman disease or type I IgG4-LAD. Rare or 
scattered tumor cells are found in the expand-
ed mantle zones, which may require meticulous 
morphologic examination at high power fields 
and the assistance of immunohistochemical 
stains. 
Type II  IgG4-LAD: reactive follicular hyperpla-
sia-like
In type II IgG4-LAD, patient usually presents 
with localized lymphadenopathy, which is fre-
quently found in the regional lymph nodes of 
extranodal IgG4-RD. Microscopically, the archi-
tecture of lymph nodes is well-preserved with 
reactive follicular hyperplasia and patent sinus-
es (Figure 3A-D). The lymphoid follicles com-
prise a reactive germinal center surrounded 
by a discrete mantle zone. The interfollicular 
areas contain mostly small reactive lympho-
cytes, mixed larger transformed lymphocytes, 
and often scattered eosinophils. The number of 
interfollicular plasma cells is variable, which is 
more evident with CD138 or IgG4 immunos-
taining. The lymphoid follicles may also have 
increased plasma cells. 
The distinction between type II IgG4-LAD and 
usual non-specific reactive follicular hyperpla-
sia is very difficult without sufficient clinical and 
laboratory information. There are some minor 
clinical and morphologic differences which may 
be more commonly noted in IgG4-LAD, includ-
ing persistent lymphadenopathy, reactive inter-
follicular plasmacytosis, and increased interfol-
Figure 3. Type II IgG4-LAD with reactive follicular hyperplasia. (A) The lymph node shows preserved architecture with 
reactive follicular hyperplasia (H&E, 40 ×). (B) The interfollicular regions reveal a mixed lymphoid population with 
frequent plasma cells and scattered eosinophils (H&E, 400 ×). (C) Abundant IgG+ cells are present (40 ×), most of 
which are also IgG4+ (D) (40 ×).
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licular eosinophils. However, none of the des- 
cribed features is specific enough to separa- 
te these two diseases. Moreover, occasional 
cases of usual reactive follicular hyperplasia 
may have a significant increase in IgG4+ plas-
ma cells. In patients with lymphadenopathy as 
an initial presentation and no documented his-
tory of extranodal IgG4-RD, it is still uncertain 
when we should consider the possibility of 
IgG4-LAD in lymph nodes with reactive follicu-
lar hyperplasia. We recommend IgG4 and IgG 
immunostains in cases with persistent and/or 
systemic lymphadenopathy and no underlying 
etiology.
Patients with rheumatoid arthritis (RA) often 
have persistent lymphadenopathy, and the dif-
ferential diagnosis from type II IgG4-LAD can 
be very tricky. Lymphadenopathy associated 
with RA typically displays hyperplastic follicles, 
which are relatively uniform in size. Intra- and 
inter-follicular reactive plasmacytosis is com-
monly present. Notably, some cases of RA 
associated lymphadenopathy may have mark-
edly increased IgG4+ cells and IgG4/IgG ratios, 
which would fit the morphologic criteria for 
IgG4-LAD. Therefore, it is important to check 
the clinical information (documented history of 
rheumatoid arthritis) and essential serum auto-
antibodies, especially rheumatoid factor.
Type III IgG4-LAD: interfollicular expansion and 
immunoblastosis
Type III IgG4-LAD usually presents with system-
ic lymphadenopathy. The architecture of lym- 
ph nodes is marked distorted with prominent 
interfollicular expansion (Figure 4A-D). Sparse 
residual lymphoid follicles are dispersed with 
normal or atrophic germinal centers (Figure 
4A). The interfollicular regions are composed of 
a spectrum of lymphocytes, including small 
lymphocytes, larger transformed cells, plasma-
cytoid cells, and plasma cells (Figure 4B and 
Figure 4. Type III IgG4-LAD with interfollicular expansion and immunoblastosis. A. The lymph node shows architec-
tural distortion with marked interfollicular expansion (H&E, 40 ×). B, C. The expanded interfollicular regions have 
frequent immunoblasts, many plasma cells, and scattered eosinophils (H&E, 200 × and 400 ×, respectively). D. 
Abundant IgG4+ cells are present in the interfollicular areas (200 ×).
IgG4-related lymphadenopathy
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4C). Reactive immunoblasts are often abun-
dant, which may form loose clusters in some 
cases. Scattered eosinophils and vascular pro-
liferation are observed.
Diagnosis of type III IgG4-LAD can be very diffi-
cult since it mimics several benign and malig-
nant conditions, and it is particularly difficult in 
cases with needle core biopsies. Acute viral 
infections, especially EBV and less commonly 
CMV, typically demonstrate marked interfollicu-
lar expansion with reactive immunoblastosis. 
Patients usually present with fever, laryngitis, 
splenomegaly, and atypical circulating cells in 
the peripheral blood. Identification of viral 
infection in the tissue sections (EBER in situ 
Table 2. Comparison between type III IgG4-LAD and angioimmunoblastic T-cell lymphoma (AITL)
Type III IgG4-LAD AITL
Presentation Often systemic lymphadenopathy, but no constitutional 
symptoms
Systemic lymphadenopathy and marked constitutional 
symptoms
Serum LDH Normal or mildly increased Markedly increased
Architecture Distorted, but at least partially preserved Markedly distorted or effaced
Vascularity Increased Markedly increased with arborization
Clear cells Usually inconspicuous Often abundant 
FDC meshwork Normal size and morphology Markedly expanded and distorted
PD1+/CD10+ cells Limited to the germinal centers Present in the atypical clear cells
EBV Negative Scattered, positive in immunoblasts
TRG@PCR Polyclonal Monoclonal
Prognosis Benign clinical course; good response to steroid therapy Poor
Figure 5. Type IV IgG4-LAD with PTGCs. (A) A PTGC is noted (left middle) in a background of reactive follicular hyper-
plasia (H&E, 40 ×). (B) A reactive germinal center contains frequent plasma cells (H&E, 600 ×). Abundant IgG+ (C) 
and IgG4+ (D) cells are noted mostly in the reactive follicles (100 ×).
IgG4-related lymphadenopathy
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hybridization for EBV and immunohistochemi-
cal stain for CMV) is crucial to reach an accu-
rate diagnosis, in conjunction with viral serolo-
gy assays. Certain medications (i.e. Dilantin) 
may induce similar morphologic changes in 
lymph nodes. 
The morphological features of type III IgG4-LAD 
overlap with those of atypical lymphoplasma-
cytic and immunoblastic proliferation (ALPIBP) 
in lymph nodes, which are associated with 
some autoimmune diseases, including rheuma-
toid arthritis (RA) and systemic lupus erythema-
tosus (SLE) [19]. Type III IgG4-LAD has to be 
distinguished from angioimmunoblastic T-cell 
lymphoma (AITL) (Table 2), particularly in cases 
with prominent interfollicular proliferation of 
high endothelial venules and abundant reactive 
immunoblasts. Patients with AITL typically pres-
ent with systemic lymphadenopathy, promin- 
ent constitutional symptoms, and markedly 
increased serum LDH levels. The lymph nodes 
of AITL reveal architectural effacement with 
proliferation of often arborized vessels. The 
expanded and distorted follicular dendritic cell 
meshwork contains clusters of atypical clear 
cells, which are CD10+ T-cells. Scattered and 
loose clusters of EBV-positive cells are mostly 
present in AITL.
Type IV IgG4-LAD: progressive transformation 
of germinal center (PTGC)-type
Patients with type IV IgG4-LAD usually present 
with an asymptomatic localized lymphadenopa-
thy in the cervical region. The lymph node 
shows preserved architecture with prominent 
follicular hyperplasia and variable degrees of 
interfollicular expansion (Figure 5A). The PTGC 
follicles are scattered in a background of hyper-
plastic follicles, and they are round to oval with 
diameters ≥ 2 times of other normal secondary 
follicles (Figure 5A). The PTGC follicles are com-
posed mostly of mantle cells, which intrude into 
the germinal centers; scattered and small clus-
ters of residual germinal center B-cells are of- 
ten noted with the PTGC follicles. Interestingly, 
frequent reactive plasma cells are noted in the 
hyperplastic germinal centers but not in the 
PTGC follicles (Figure 5B). The interfollicular 
areas contain a mixed population of lympho-
cytes with frequent eosinophils. Characteri- 
stically, in this type of IgG4-LAD, the IgG4+ cells 
are mostly localized in the hyperplastic germi-
nal centers (Figure 5C and 5D), with only scat-
tered ones in the interfollicular areas. 
In general, PTGCs occur in approximately 3.5% 
of cases of reactive lymphadenopathy [20, 21]. 
PTGCs are associated with nodular lymphocyte 
predominant Hodgkin lymphoma (NLPHL), and 
they may arise preceding or following NLPHL or 
in separate lymph nodes at the same time. 
Therefore, for lymph nodes with PTGCs, it is 
essential to search the LP cells (lymphocyte-
predominant cells) at high magnifications in the 
PTGC follicles to rule out NLPHL. 
Recent studies have proven that approximately 
one-third of cases with PTGCs eventually pro-
gressed to extranodal IgG4-RD, systemic dis-
ease, or both during the follow-up period [22]. 
In a study from Sato, et al, 40 of 62 PTGC cases 
(65%) fulfilled the histological criteria of IgG4-
LAD, with IgG4+ cells >100 per HPF and an 
IgG4/IgG ratio > 40% (IgG4+ PTGC) [22]. Thirty-
four patients with IgG4+ PTGCs were followed 
by regular imaging, laboratory findings and clini-
cal evaluation during a median period of 26 
months; totally 18 patients (18/34, 53%) were 
discovered to have extranodal IgG4-RD. Th- 
erefore, PTGC alone has a high association with 
Table 3. Comparison between type IV IgG4-LAD and IgG4-negative PTGC
Type IV IgG4-LAD Usual IgG4 Negative PTGC
Age/gender Mostly middle-aged or elderly male Younger age, slight male predominance
Locations Localized or systemic,  axillary, mediastinal, intraabdominal Often isolated, mostly cervical, axillary or inguinal
Duration Persistent Recurs in 20% cases
Low-power features Similar with PTGCs Similar with PTGCs
Plasma cells in germinal center Markedly increased Usually not increased
Interfollicular eosinophils Often increased May or may not be increased
IgG4, IgG4/IgG Markedly increased Not increased
Serum IgG4 Mostly raised Not raised
Extranodal IgG4-RD Often present No
Risk Systemic IgG4-related disease NLPHL
IgG4-related lymphadenopathy
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development of extranodal IgG4-RD, with an 
overall risk of approximately 34% (65% × 53%). 
The distinction of type IV IgG4-LAD (IgG4+ 
PTGC) from usual IgG4-negative PTGC mainly 
relies on the clinical examination and follow-up, 
although some clinicopathologic differences 
exist (Table 3). Patients with type IV IgG4-LAD 
are usually older and have a higher incidence of 
submandibular lymph node involvement than 
those with IgG4-negative PTGCs. In contrast to 
cases with IgG4-negative PTGCs, patients with 
type IV IgG4-LAD have persistent lymphade-
nopathy if no further treatment, and the hy- 
perplastic follicles contain many plasma cells, 
which are more obvious with CD138 or IgG4 
immunostaining. The interfollicular regions of- 
ten have increased eosinophils.
Taken together, we recommend performing IgG 
and IgG4 immunostains in all lymph node cases 
with PTGCs after excluding NLPHL since PTGCs 
have a high association with nodal and extrano-
dal IgG4-RD. So far, there are no data on the 
pediatric PTGCs and more studies are neces-
sary to evaluate the association of pediatric 
PTGCs with IgG4-RD. 
Type V IgG4-LAD: inflammatory pseudotumor 
(IPT)-like
This type is the least common one and very 
rare. Patients usually present with asymptom-
atic localized lymphadenopathy. Histologically, 
the involved lymph nodes show focal infiltration 
by poorly demarcated fibrous tissue with hyalin-
ization, which is sprinkled with lymphocytes, 
plasma cells and scattered eosinophils. The 
fibrosis may be arranged in a storiform pattern 
and contain fibroblasts. Focal residual normal 
lymphoid tissue is present with hyperplastic fol-
licles. The nodal infiltration is similar to that in 
extranodal IgG4-RD except that there is lack of 
obliterative phlebitis.
The histological findings often resemble nodal 
IPT (Table 4). However, patients with nodal IPT 
typically present with constitutional symptoms, 
including fever, fatigue, weight loss, and night 
sweats, whereas patients with type V IgG4-LAD 
typically lack these symptoms. Morpho- 
logically, nodal IPT forms a well-circumscribed 
mass lesion, which is composed of abundant 
spindle tumor cells with evenly distributed lym-
phocytes and plasma cells. The spindle cells 
express smooth muscle actin in most cases 
and ALK in a significant subset of cases. 
Further differential diagnoses of IgG4-LAD
In addition to the differential diagnoses listed 
above in each subtype of IgG4-LAD, other reac-
tive and neoplastic processes should also be 
considered. In general, lymphadenopathy in 
IgG4-LAD is localized or generalized but usually 
asymptomatic except mass effects in some 
cases. The cases with systemic lymphadenopa-
thy may clinically resemble lymphoma, multi-
centric Castleman disease, and metastatic 
malignant tumor. However, the lymph nodes in 
IgG4-LAD are generally not very large and typi-
cally less than 2 cm in greatest dimension. The 
patients usually do not present with constitu-
tional symptoms, including fever, night sweats, 
and weight loss. Serum lactate dehydrogenase 
level is normal or only minimally elevated. It is 
important to examine the tissue sections to 
rule out lymphoma, infection, autoimmune pro-
cess, and medication effect, with the assis-
tance of clinical findings and ancillary studies. 
IgG4-LAD may display the five major morpho-
logic patterns with mixed features in some 
cases, but coagulative necrosis, epithelioid 
Table 4. Comparison between type V IgG4-LAD and nodal inflammatory myofibroblastic tumor (IMT)
Type V IgG4-LAD Nodal IMT
Nature of lesion An reactive inflammatory fibrosclerosing process A neoplastic process in many cases
Symptoms Usually no symptoms of fever, fatigue, weight loss, and night sweats Usually with symptoms of fever, fatigue, weight loss, 
and night sweats
Clinical findings Mass lesion, variable symptoms, often associated with systemic IgG4-RD Mass lesion, not often with extranodal involvement
Gross features Usually a poorly demarcated mass lesion A discrete well-defined mass lesion
Histologic features Fibrosclerotic lesion with poorly defined borders; patchy lymphoplasma-
cytic infiltration; mixed spindle fibroblasts and myofibroblasts
Well-demarcated lesion; evenly distributed lymphoplas-
macytic cells; presence of abundant spindle tumor cells
IHC No significant actin+ myofibroblasts; increased IgG4+ cells and IgG4/
IgG ratios
Abundant actin+ cells; ALK+/-; no increased IgG4+ 
cells or IgG4/IgG ratio
Serum IgG4 Often elevated Normal
IgG4-related lymphadenopathy
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granulomas, and prominent neutrophil infiltra-
tion are usually absent [6].
Usual reactive lymphadenopathy
The morphologic findings and immunohisto-
chemistry (IgG4+ cells ≥ 100/HFP and IgG4/
IgG ≥ 40%) in lymph nodes are essential but 
not sufficient for diagnosis of IgG4-LAD. Non-
IgG4 associated lymphadenopathy may show 
a significant increase in IgG4+ cells and IgG4/
IgG ratio, including rheumatoid arthritis, Rosai-
Dorfman disease, and multicentric Castleman 
disease [15, 17, 23-25]. Recently, it has been 
noticed that even nonspecific reactive lymph-
adenopathies many have increased IgG4+ cells 
and IgG4/IgG ratio. In an unpublished study, we 
collected 89 consecutive cases of reactive 
lymph nodes, which were stained for IgG4. Up 
to 36% of cases showed a significant increase 
in IgG4+ cells and IgG4/IgG ratios; during retro-
spective studies and a short period of follow-
up, only a small proportion of patients were 
found to have extranodal IgG4-RD. The signifi-
cance of the IgG4+ cells in many non-specific 
cases is unclear. Our data, in conjunction with 
others [17], indicate that a substantial number 
of non-specific or isolated lymphadenopathy 
with abundant IgG4+ cells may be irrelevant to 
IgG4-RD. Therefore, an accurate diagnosis of 
IgG4-LAD requires correlation with further clini-
cal findings and laboratory studies. Moreover, 
an elevated serum IgG4 level (> 135 mg/dL) is 
helpful but not essential for diagnosis since 
serum IgG4 levels may be elevated in non-IgG4 
associated conditions as well.
Hyper-interleukin-6 (IL-6) syndromes
Hyper-IL-6 syndromes, including MCD and RA 
as discussed above, frequently involve lymph 
nodes, which sometimes fulfill the histological 
diagnostic criteria for IgG4-LAD with significant-
ly increased IgG4+ cells and IgG4/IgG ratios. In 
hyper-IL-6 syndromes, with the effects of IL-6, 
the serum levels of IgA, IgG and subclasses, 
IgE, IgM, and C-reactive protein (CRP) are glob-
ally elevated. In addition, patients present wi- 
th anemia, thrombocytosis, hypoalbuminemia, 
and hypocholesterolemia, which are also relat-
ed to high IL-6 levels. In IgG4-LAD, the major 
serologic abnormalities are elevated IgG (most-
ly due to IgG4) and IgE, whereas other parame-
ters are typically within normal limits or only 
mildly elevated (Table 5). Therefore, histologic 
findings and immunohistochemical stains for 
IgG4 are not sufficient to separate IgG4-LAD 
from hyper-IL-6 syndrome related lymphade-
nopathy; clinical presentations and further lab-
oratory analyses are crucial to separate the two 
entities. C-reactive protein and serum IL-6 lev-
els are significantly elevated in MCD, and they 
are useful markers for differentiating between 
IgG4-LAD and MCD.
Rosai-Dorfman diseases
A subset (up to 30%) of nodal and extranodal 
Rosai-Dorfman diseases (RDD) shows features 
of IgG4-RD with significantly increased IgG4+ 
cells and IgG4/IgG ratio [26, 27], indicating 
that these two diseases may overlap in certain 
aspects, although the studies from Liu, et al. 
suggested that RDD does not belong to the 
spectrum of IgG4-RD [28]. We also encoun-
tered two nodal cases of RDD with a prominent 
increase in IgG4+ cells and IgG4/IgG ratio, and 
interestingly both patients also had markedly 
elevated serum IgG4 levels. One patient pre-
sented with systemic lymphadenopathy, and 
the lymph nodes were significantly reduced in 
size after treatment with steroids and low-dose 
rituximab. Extranodal RDD may also closely 
Table 5. Comparison between IgG4-related disease and hyper-IL-6 syndrome
IgG4-Related Disease Hyper-IL-6 Syndrome
Serum immunoglobulin IgG↑ (mainly IgG4↑), IgE↑ IgG↑ (IgG1~IgG4↑), IgA↑, IgM-/↑, IgE↑
Serum IgG4/IgG ratio Elevated Normal or slightly elevated
Serum IL-6 Normal or slightly elevated Elevated
Serum CRP Normal or slightly elevated Elevated
Thrombocytosis No Yes
Anemia No Yes
Hypoalbuminemia No Yes
Hypocholesterolemia No Yes
↑: increased.
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resemble IgG4-RD with prominent fibrosis and 
lymphoplasmacytic infiltrate, and the charac-
teristic histiocytes with emperipolesis may not 
be evident compared to the nodal cases; it can 
be challenging to make an accurate diagnosis 
of these extranodal RDD, particularly in cases 
with elevated IgG4+ cells in the tissue.
Lymphoma
T-cell and B-cell lymphomas must be excluded 
incases suspicious for IgG4-LAD. For instanc-
es, lymphocyte-rich CHL needs to be ruled out 
in lymph nodes with Castleman-like features, 
NLPHL has to be excluded in cases with PTGC, 
and AITL is also in the differential diagnoses in 
cases with marked interfollicular expansion, 
prominent vascular proliferation and immuno-
blastosis. Detailed clinical information, meticu-
lous morphologic examination, and necessary 
ancillary studies are critical to reach an accu-
rate diagnosis. The lymph node cases with flor-
id lymphoplasmacytic infiltrates may mimic pri-
mary nodal lymphoma, especially nodal mar-
ginal zone lymphoma and lymphoplasmacytic 
lymphoma with plasmacytic differentiation. In 
lymphoma cases, the lymphoid and plasmacyt-
ic populations often exhibit atypical morpho-
logic features, and they may express aberrant 
markers with light chain restriction by flow cyto-
metric assays, immunohistochemical stains, 
and in situ hybridization studies. 
We have to point out that certain B-cell lympho-
mas and plasma cell neoplasms may express 
IgG4, which can potentially resemble IgG4-RD 
particularly in the extranodal sites [29-31]. In a 
recent study, 19 cases of orbital MALT lympho-
ma were investigated for IgG4-related disease, 
and in 10 out of 19 cases the lymphoma cells 
had a significant expression of IgG4, which 
would meet the criteria of IgG4-RD immunohis-
tochemi-cally [31]. 
Diagnostic algorithm for IgG4-LAD
When should we consider IgG4 immunostain 
in reactive lymph nodes?
IgG4 immunostain is certainly not recommend-
ed for every single reactive lymph node during 
our routine practice, and the decision may be 
made based upon the overall clinical presenta-
tions and morphologic changes. We feel that 
the IgG4 immunostain may not be necessary 
under the following circumstances, to list a few 
examples: (1) Lymphadenopathy is limited to a 
single node or a localized region in patients 
with no clinical suspicion for IgG4-RD; (2) 
Lymphadenopathy in patients with known clini-
cal history of infections, autoimmune disorders 
(i.e. RA and SLE) or certain medications (i.e. 
Dilantin and methotrexate); (3) Lymphadeno- 
pathy associated with malignancies or proce-
dures in the vicinity. It is not uncommon to iden-
tify very large reactive lymph nodes in regional 
lymph node dissection sample for carcinoma or 
melanoma, despite no metastatic tumor in the 
lymph nodes; (4) Rather small quiescent lymph 
node with no significant follicular/interfollicular 
hyperplasia and no marked increase in reactive 
plasma cells and eosinophils; and (5) Reactive 
lymphadenopathy with known etiology, i.e. der-
matopathic lymphadenopathy and Kikuchi-
Fujimoto lymphadenitis. 
In general, we recommend IgG and IgG4 immu-
nostains in the following settings: (1) Lym- 
phadenopathy in patients with a documented 
clinical history of extranodal IgG4-RD; (2) 
Persistent and/or systemic lymphadenopathy 
with no underlying causes, including lympho-
ma, autoimmune diseases, medications, and 
infections; (3) Lymphadenopathy with increased 
plasma cells in germinal centers and/or inter-
follicular regions; and (4) Reactive lymph nodes 
with PTGCs after excluding NLPHL.
How should we render the diagnosis of reac-
tive lymph nodes with increased IgG4+ cells?
As we emphasized above, the presence of com-
patible histology and immunohistochemistry 
(abundant IgG4+ cells and high IgG4/IgG ratio) 
is essential but not sufficient for a diagnosis of 
IgG4-LAD, and appropriate clinical findings and 
laboratory tests are still required for an accu-
rate diagnosis. Many other non-IgG4-related 
diseases may meet these criteria, including 
rheumatoid arthritis, multicentric Castleman 
disease, and even some non-specific reactive 
conditions. Therefore, great caution should be 
taken in diagnosis of IgG4-LAD. We recommend 
the following algorithms in working up reactive 
lymph nodes with markedly increased IgG4+ 
cells and IgG4/IgG ratio:
1. Specific entities have to be excluded first 
based on the clinical features, morphologic 
changes and laboratory studies, including mul-
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ticentric Castleman disease, rheumatoid arthri-
tis, Rosai-Dorfman disease, and other inflam-
matory/infectious process. For example, if the 
morphology and immunohistochemistry fit well 
with Rosai-Dorfman disease, the nodal disease 
may be signed out as “Rosai-Dorfman disease 
with increased IgG4+ cells”; 2. If the patient 
has documented or newly confirmed extranodal 
IgG4-RD, the final diagnosis in the lymph node 
may be rendered as “consistent with IgG4-
related lymphadenopathy”; 3. It is not uncom-
mon that the lymphadenopathy occurs as the 
initial presentation in patients with no docu-
mented history of IgG4-RD, which often places 
great challenge to the pathologists for a defini-
tive diagnosis. Under these circumstances, if 
the lymphadenopathy is systemic and/or per-
sistent with no apparent underlying etiology, a 
tentative diagnosis can be made descriptively 
as “reactive lymphoid hyperplasia with increa- 
sed IgG4+ cells; possible IgG4-related lymph-
adenopathy if clinical presentations and labo-
ratory results fit”. A comment is necessary to 
recommend further clinical workup and correla-
tion, including serology studies (particularly 
immunoglobulin fractions and levels) and pos-
sibly biopsies of extranodal lesions if present. 
The patient may be managed with steroids, 
methotrexate or rituximab if clinical treatment 
is required to relieve the symptoms; 4. Some 
patients may have localized lymphadenopathy 
and no documented history of extranodal IgG4-
RD, and morphologically the suspicion for IgG4-
LAD is not high. Therefore, it is appropriate to 
make a descriptive diagnosis of “reactive lym-
phoid hyperplasia with increased IgG4+cells; 
significance unclear”. In the comment, further 
clinical examinations, laboratory studies, and 
close follow-up should be advised.
Conclusion
IgG4-LAD is a clinicopathologic entity, and an 
accurate diagnosis has to be established based 
on the overall clinical presentations, laboratory 
studies and histologic findings. The morpholog-
ic changes and immunohistochemistry (> 100 
IgG4+ cells/HPF and IgG4/IgG ratio > 40%) are 
essential but not sufficient for diagnosis since 
other non-IgG4-related conditions may fulfill 
these criteria and have to be excluded, includ-
ing autoimmune diseases, infections, neoplas-
tic processes, and non-specific reactive ch- 
anges.
IgG4 and IgG immunostains are recommended 
in systemic and/or persistent reactive lymph-
adenopathy with no obvious underlying causes, 
particularly in cases with reactive plasmacyto-
sis and PTGCs. For reactive lymph nodes with 
markedly increased IgG4+ cells and IgG4/IgG 
ratios, the interpretation has to be formulated 
based upon the clinical history (documented 
extranodal IgG4-RD or not), clinical examina-
tions (possible presence of IgG4-RD or not), 
and laboratory studies (particularly levels of 
immunoglobulin subtypes and IgG fractions, 
autoimmune antibodies, and IL-6). Effective 
communication between the pathologists and 
the treating physicians is also critical in estab-
lishing a final diagnosis and for further manage-
ment of patients. 
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